Pandorum and Nucelion manufacturing partnership to advance two designer-exosome programmes in ophthalmology

image credit- freepik

Hyderabad-based Nucelion Therapeutics, a next-generation Cell and Gene Therapy CDMO and wholly owned subsidiary of Bharat Biotech, and Bengaluru-headquartered Pandorum Technologies, a Tissue Engineering and Regenerative Medicine company, have announced that their manufacturing partnership will advance two PRIP-backed ophthalmology projects focused on developing investigational therapies for advanced keratopathy and wet age-related macular degeneration (wet AMD).

Pandorum is developing cell-free regenerative medicines based on designer exosomes that carry biological signals involved in communication between cells. The biological activity of these exosomes is tuned to address inflammation, fibrosis and vascular pathology while supporting tissue repair. The platform connects the manufacturing process, the product, its biological activities and the corresponding tissue response in an integrated learning loop.

Through its collaboration with Nucelion, Pandorum is connecting programmable regenerative-medicine design with reproducible manufacturing and indication-specific development—while building that capability in India with national research support.

Nucelion’s role in the two investigational ophthalmology projects will centre on process development and manufacturing support for Pandorum’s designer exosomes, aligned with the requirements and development stage of each programme. This partnership reflects the role specialised manufacturing capabilities can play in the development of emerging regenerative medicines.

The broader Pandorum–Nucelion collaboration is intended to provide material manufactured under Good Manufacturing Practice (GMP) for clinical studies in India and abroad, subject to applicable regulatory approvals.

The advanced-keratopathy programme by Pandorum is directed towards clinical evaluation of investigational therapies for severe corneal disease. The wet-AMD programme extends the platform into retinal disease, with its current project focused on preclinical development and preparation for subsequent clinical translation. 

The two projects have a combined planned outlay of Rs 16.97 crore, comprising up to Rs 8 crore in funding under the PRIP scheme.